Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tempest Therapeutics Inc (NQ: TPST ) 1.370 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tempest Therapeutics Inc < Previous 1 2 Next > Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 20, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs September 18, 2024 Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study From Tempest Therapeutics Via GlobeNewswire Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 From Tempest Therapeutics Via GlobeNewswire “Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX November 15, 2023 Via AB Newswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 23, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance August 21, 2024 Expansion of leadership team to strengthen global clinical expertise From Tempest Therapeutics Via GlobeNewswire Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma August 15, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm June 20, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma June 18, 2024 Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET From Tempest Therapeutics Via GlobeNewswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Tempest Therapeutics Via GlobeNewswire Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) May 31, 2024 From Glancy Prongay & Murray LLP Via Business Wire Tempest to Participate in Upcoming Investor Conferences May 21, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 26, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting April 09, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications April 04, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports Year End 2023 Financial Results and Provides Business Update March 19, 2024 From Tempest Therapeutics Via GlobeNewswire Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) March 14, 2024 From Glancy Prongay & Murray LLP Via Business Wire Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types March 12, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting March 05, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest to Present at the 44th Annual TD Cowen Healthcare Conference February 26, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024 January 30, 2024 Via AB Newswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Tempest Therapeutics Via GlobeNewswire Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 01, 2023 From Tempest Therapeutics Via GlobeNewswire Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference November 20, 2023 From Tempest Therapeutics Via GlobeNewswire Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK November 14, 2023 Via AB Newswire Exposures Product Safety Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update November 08, 2023 From Tempest Therapeutics Via GlobeNewswire MarketBeat Week in Review – 10/16 - 10/20 October 21, 2023 All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control Via MarketBeat Topics Bonds Economy Exposures Debt Markets Economy Interest Rates < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.